A Phase 1, Randomized, Double-Blind, Placebo-controlled, Dose-ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-vector Based Norovirus Vaccine (VXA‑G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-controlled, Dose-ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-vector Based Norovirus Vaccine (VXA‑G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Norovirus vaccine (Primary)
  • Indications Norovirus infections
  • Focus Adverse reactions
  • Sponsors Vaxart
  • Most Recent Events

    • 06 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Aug 2017.
    • 14 Feb 2017 Status changed from recruiting to active, no longer recruiting, according to a Vaxart media release.
    • 14 Feb 2017 Results published in a Vaxart media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top